TurboCHO™ Bi-specific Antibody Expression
70+ different formats of bsAb produced; 5,000+ bsAb projects delivered; 6+ optimized processes provided
Receive your quote directly from the manufacturer.
"Bi-specific antibodies (bsAbs) demonstrate novel functionalities that yield remarkable promise in improving the drug therapeutic efficacy through the recognition and targeting of two different antigens or epitopes. Although the optimized purification of mAbs serve as a good starting point for the purification of bsAbs, further optimization cannot be fully eliminated due to the differences in their intrinsic structural.
At GenScript, with the advanced 1) Specialized format design, 2) AI-driven codon optimization, 3) Optimized plasmid ratio, 4) Optimized production process, 5) Proprietary TurboCHO™cell line and 6) Multiple purification columns, GenScript can handle your bsAb projects from micrograms-level to grams-level seamlessly."
Mastering multi-specific antibody production for next-gen drug discovery
The ongoing AI revolution opens up a new era of antibody design, with a focus on bi-specific antibodies. Gain insight into how artificial intelligence (AI) is assisting next-generation drug discovery in the production of multispecific antibodies.
Enhance productivity and purity in next-generation bispecific antibody manufacturing
Monday, July 14, at 15:00 BST | 16:00 CEST | 10:00 EDT | 7:00 PDT
Bispecific antibodies (BsAbs) are at the forefront of next-generation antibody therapies, offering immense potential but also presenting significant production challenges, such as secretion inefficiencies, chain mispairing, and impurity formation.
Join Dr. Heng Tai Liew, Senior Protein Scientist at GenScript Biotech and discover how GenScript's TurboCHO™ technology overcomes these hurdles through an integrated and iterative workflow that optimizes cell lines, vectors, and media using Design of Experiments (DOE) to refine chain ratios and boost yields. This approach is complemented by a both streamlined and customized purification strategy that utilizes advanced chromatography techniques, enabling selective impurity removal based on molecular differences to achieve superior purity.
Real-world case studies validate the efficacy of this systematic method, demonstrating its capacity to resolve common BsAb production obstacles and support a range of formats from early-stage development through to clinical-scale manufacturing.
Key learning objectives:
- Characterize the key challenges in BsAb production, including issues related to secretion efficiency, chain mispairing, and impurity accumulation, and their impact on the scalability and therapeutic potential of next-generation antibody-based therapies.
- Learn how GenScript’s TurboCHO technology optimizes the production process, including the use of DOE-driven cycles to refine cell lines, vectors, media, and chain ratios for improved yields.
- Understand how GenScript leverages chromatography techniques to achieve high-purity bispecific antibodies and effectively address common production challenges from development to clinical application.
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes. If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
